Clinical trial registry record

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 15, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07453823
Last registry update
April 15, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
Chr Hansen - part of Novonesis
Enrollment
90
Countries
Ireland
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · OTHER · QUADRUPLE
Evidence population
Human clinical study registration
Participants
90
Population
ALL · 50 Years to 70 Years
Duration
2026-03-18 to 2026-12-01
Intervention
Synbiotic; Placebo
Comparator
Synbiotic; Placebo
Outcomes measured
Bifidobacterium abundance — From baseline to end of intervention at 8 weeks; Stool frequency — From baseline to end of intervention at 8 weeks; Fecal acetate — From baseline to end of intervention at 8 weeks.; Fecal propionate — From baseline to end of intervention at 8 weeks.; Fecal butyrate — From baseline to end of intervention at 8 weeks; Zonulin — From baseline to end of intervention at 8 weeks; Lipopolysaccharide binding protein (LPS-BP) — From baseline to end of intervention at 8 weeks; Interleukin 6 (IL-6) — From baseline to end of intervention at 8 weeks; High-sensitivity C-Reactive Protein (hsCRP) — From baseline to end of intervention at 8 weeks; Fecal Short-Chain Fatty Acids (SCFA) — From baseline to end of intervention at 8 weeks; Stool consistency — From baseline to end of intervention at 8 weeks; Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score — From baseline to end of intervent…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Probiotics and prebiotics · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

probiotics prebiotics aging
Read the original source →Export JSON